Recent applications of benchmark dose method for estimation of reference cadmium exposure for renal effects in man.
The initial sign of cadmium (Cd)-induced renal effects is tubular damage, followed by glomerular damage. For the prevention of Cd-induced renal effects, it is essential to establish the reference exposure below which the risk of adverse health effects is low. In earlier Japanese studies, the estimated reference exposure of creatinine (cre)-adjusted urinary cadmium for renal tubular effect ranged from 1.6 to 4.0 microg/g cre in men and 2.3 to 4.6 microg/g cre in women. The benchmark dose (BMD) is defined as the exposure that corresponds to a certain response change from the background. The lower 95% confidence limit of the BMD (BMDL) can be used in risk assessment as a replacement for the no observed adverse effect level. This is a review of all relevant BMDL of Cd exposure for renal effects estimated so far. Based on studies in Japan, the best estimate is considered to be 1.5-3.2 microg/g cre for urinary Cd, 0.09-0.13 mg/kg for rice Cd concentration, and 0.9-1.4 g Cd for lifetime Cd intake. These BMDLs for renal effects were generally lower than the reference exposure expected from earlier studies, indicating the importance of further discussion regarding comprehensive measures to decrease the Cd exposure in the general population.
Suwazono
Yasushi
Y
Department of Occupational and Environmental Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuoku, Chiba 260-8670, Japan. suwa@faculty.chiba-u.jp
Uetani
Mirei
M
Akesson
Agneta
A
Vahter
Marie
M
D000328:Adult; D019985:Benchmarking; D002104:Cadmium / Q000378:metabolism / Q000592:standards* / Q000652:urine; D002681:China / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004781:Environmental Exposure / Q000592:standards* / Q000706:statistics & numerical data; D004785:Environmental Pollutants / Q000378:metabolism / Q000592:standards* / Q000652:urine; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007674:Kidney Diseases / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012275:Oryza / Q000378:metabolism; D012016:Reference Values; D013548:Sweden / Q000453:epidemiology
D004785:Environmental Pollutants; D002104:Cadmium